

10/089787

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	El-Sherbeini, Mohamed <i>et al.</i>	
Serial No.:	10/089,787	Case No.: 20522P
Filed:	April 3, 2002	
For:	MraY GENE AND ENZYME PSEUDOMONAS AERUGINOSA	

Authorized Officer:

Assistant Commissioner for Patents  
 Box PCT  
 Washington, D.C. 20231

RESPONSE TO COMPLY WITH SEQUENCE REQUIREMENT


Sir:

The following statement is made as required by 37 C.F.R. § 1.821(f).

I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (c) and (e), respectively, are the same and contain no new matter.

Respectfully submitted,

**EXPRESS MAIL CERTIFICATE**  
 DATE OF DEPOSIT August 5, 2002  
 EXPRESS MAIL NO. EL920759449US  
 I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
 BEING DEPOSITED WITH THE UNITED STATES POSTAL  
 SERVICE AS EXPRESS MAIL "POST OFFICE TO  
 ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN  
 AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER  
 FOR PATENTS, WASHINGTON, D.C., 20231  
 MAILED BY Christina Cuffe  
 DATE 8-5-02

By   
 Anna L. Cocuzzo  
 Reg. No. 42,452  
 Attorney for Applicant(s)

MERCK & CO., INC.  
 P.O. Box 2000  
 Rahway, New Jersey 07065-0907  
 (732) 594-1273

Date: August 5, 2002

Rec'd PCT TO 05 AUG 2002

10/089787



UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box PCT  
 United States Patent and Trademark Office  
 Washington, D.C. 20231  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/089,787	Mohamed El Sherbeini	20522P

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/US00/27056

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

09/29/2000

10/04/1999

Merck & CO INC  
 Patent Department RY60-30  
 P O Box 2000  
 126 East Lincoln Avenue  
 Rahway, NJ 07065-0970

CONFIRMATION NO. 1046

371 FORMALITIES LETTER



\*OC000000008352679\*

Date Mailed: 06/27/2002

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Copy of IPE Report
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration

#### EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT August 5, 2002EXPRESS MAIL NO. EL920759449US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
 BEING DEPOSITED WITH THE UNITED STATES POSTAL  
 SERVICE AS EXPRESS MAIL "POST OFFICE TO  
 ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN  
 AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER  
 FOR PATENTS, WASHINGTON, D.C., 20231

MAILED BY Christine Cappel  
 DATE 8-15-02

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

• The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37

CFR 1.821(e).

■ **APPLICANT MUST PROVIDE:**

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

● For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

WINSTON M ALVARADO

Telephone: (703) 305-6421

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/089,787	PCT/US00/27056	20522P